Genprex (NASDAQ:GNPX) Sees Unusually-High Trading Volume
Shares of Genprex Inc (NASDAQ:GNPX) saw unusually-strong trading volume on Wednesday . Approximately 721,933 shares changed hands during mid-day trading, an increase of 1,614% from the previous session’s volume of 42,115 shares.The stock last traded at $0.88 and had previously closed at $0.88.
A number of brokerages have weighed in on GNPX. Zacks Investment Research upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research note on Tuesday, June 18th. ValuEngine upgraded shares of Genprex from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
The firm has a market capitalization of $13.78 million, a PE ratio of -1.00 and a beta of 1.44. The business’s 50 day simple moving average is $0.92 and its two-hundred day simple moving average is $1.40.
A hedge fund recently bought a new stake in Genprex stock. Citadel Advisors LLC purchased a new position in Genprex Inc (NASDAQ:GNPX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned approximately 0.20% of Genprex as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 5.17% of the company’s stock.
About Genprex (NASDAQ:GNPX)
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.